Literature DB >> 14644827

Oral contraceptives and reproductive system cancer.

E Deligeoroglou1, E Michailidis, G Creatsas.   

Abstract

Extensive research during the last 20 years has shown that oral contraceptives are safe. Several recent epidemiological studies have confirmed that combined oral contraceptives (COCs) provide substantial protection against endometrial and ovarian cancer, and this protection is long-lasting and may persist for 15 or more years after termination of OC use. In many studies COCs have been associated with an increased risk of cervical abnormalities and cervical cancer, but there might be alternative explanations for these epidemiological associations (COC users can start having sexual intercourse at an earlier age, they have more sexual partners, and they rarely use barrier methods of contraception), so OCs act as a promoter for HPV-induced carcinogenesis. Finally, women who are currently using COCs or have used them in the past 10 years are at a slightly increased risk of having breast cancer during the next 10 years, although the additional cancers diagnosed tend to be localized to the breast and they are less advanced clinically than the cancers diagnosed in those who have never used COCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644827     DOI: 10.1196/annals.1290.023

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Authors:  Maria B Koenigs; Armida Lefranc-Torres; Juliana Bonilla-Velez; Krupal B Patel; D Neil Hayes; Krzysztof Glomski; Paul M Busse; Annie W Chan; John R Clark; Daniel G Deschler; Kevin S Emerick; Rebecca J Hammon; Lori J Wirth; Derrick T Lin; Edmund A Mroz; William C Faquin; James W Rocco
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

2.  Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells.

Authors:  Mayank Singh; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2010-10-13       Impact factor: 3.396

3.  Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes.

Authors:  L M Scott; P Durant; S Leone-Kabler; C E Wood; T C Register; A Townsend; J M Cline
Journal:  J Steroid Biochem Mol Biol       Date:  2008-10-08       Impact factor: 4.292

4.  Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors.

Authors:  Ernest K Amankwah; Christine M Friedenreich; Anthony M Magliocco; Rollin Brant; Thomas Speidel; Wahida Rahman; Linda S Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-15       Impact factor: 4.254

5.  Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer.

Authors:  Carine Bossard; Muriel Busson; David Vindrieux; Françoise Gaudin; Véronique Machelon; Madly Brigitte; Carine Jacquard; Arnaud Pillon; Patrick Balaguer; Karl Balabanian; Gwendal Lazennec
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

6.  Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004.

Authors:  M Vessey; R Painter
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640

7.  Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications.

Authors:  Zsuzsanna Suba
Journal:  Onco Targets Ther       Date:  2014-01-23       Impact factor: 4.147

Review 8.  Circulatory estrogen level protects against breast cancer in obese women.

Authors:  Zsuzsanna Suba
Journal:  Recent Pat Anticancer Drug Discov       Date:  2013-05       Impact factor: 4.169

9.  Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women.

Authors:  Norma McFarlane-Anderson; Patience E Bazuaye; Maria D Jackson; Monica Smikle; Horace M Fletcher
Journal:  BMC Womens Health       Date:  2008-05-30       Impact factor: 2.809

10.  Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3.

Authors:  Shengnan Li; Kuo Jiang; Jia Li; Xiaohua Hao; Wenguang Chu; Ceng Luo; Yuanyuan Zhu; Rougang Xie; Biliang Chen
Journal:  J Ovarian Res       Date:  2020-02-22       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.